TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21685377

Group type: EXPERIMENTAL
Intervention: Mediated decision support related to prostate cancer screening
Number of subjects: 146
Study: 19151384

Group type: EXPERIMENTAL
Intervention: Real therapy
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 221
Study: 17474541

Group type: EXPERIMENTAL
Intervention: Test syrup containing 15 mg dextromethorphan hydrobromide, 7.5 mg doxylamine succinate, 600 mg paracetamol, and 8 mg ephedrine sulfate (Group T)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo syrup (Group P)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Test syrup (Group T)
Number of subjects: 432
Study: 15465207

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 1143
Study: 12195835

Group type: EXPERIMENTAL
Intervention: Formoterol (4, 5, 9, or 18 micrograms b.i.d. via Turbuhaler)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms t.i.d. via pMDI with spacer)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 9810788

Group type: EXPERIMENTAL
Intervention: Infrared tympanic membrane thermometry (LighTouch LTX Pedi-Q thermometer)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Axillary temperature measurement (mercury-in-glass thermometers)
Number of subjects: 313
Study: 8577941

Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) at 11.4 pmol/kg/min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Urodilatin (URO) at 17.1 pmol/kg/min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cardiodilatin/atrial natriuretic peptide (CDD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Salbutamol (SALB)
Number of subjects: 36
Study: 2229860

Group type: EXPERIMENTAL
Intervention: Multidisciplinary-team approach to patient care
Number of subjects: 436
Study: 348553

Group type: EXPERIMENTAL
Intervention: Milk B (12.5 g of lactose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Milk C (37.5 g of lactose)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Milk A (no lactose)
Number of subjects: 150
Study: 30791510

Group type: EXPERIMENTAL
Intervention: Safety signs depicting critical slopes in degrees
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Safety signs depicting critical slopes as percent values
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Previous involvement in machinery-related incidents
Number of subjects: 18
Study: 27902988

Group type: EXPERIMENTAL
Intervention: Smell and taste of milk before each feed
Number of subjects: 51

Group type: COMPARATOR
Intervention: No exposure to the smell and taste of milk (control)
Number of subjects: 51
Study: 26115809

Group type: EXPERIMENTAL
Intervention: Endovascular management
Number of subjects: 37

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 37
Study: 23382300

Group type: EXPERIMENTAL
Intervention: Intense combined dietary-behavioral-physical activity intervention
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (age, gender, and obesity matched)
Number of subjects: 22
Study: 21937521

Group type: EXPERIMENTAL
Intervention: Hyperthermia
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hyperthermia and Sham treatment
Number of subjects: 22
Study: 19657277

Group type: EXPERIMENTAL
Intervention: High Dk soft lens wear
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High Dk rigid gas-permeable lens wear
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Eye rubbing
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (left eye)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Peripheral epithelium
Number of subjects: 10
Study: 17466110

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behaviour therapy
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Group cognitive behaviour therapy
Number of subjects: 301

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 301
Study: 15154923

Group type: EXPERIMENTAL
Intervention: Cacao bean husk extract (CBH) rinsing for 4 days, before and after meals and before sleeping.
Number of subjects: 49

Group type: COMPARATOR
Intervention: 1% ethanol rinsing (control group).
Number of subjects: 49
Study: 11529210

Group type: EXPERIMENTAL
Intervention: Prone positioning for six or more hours daily for 10 days
Number of subjects: 304

Group type: COMPARATOR
Intervention: Conventional treatment in the supine position
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Prone positioning
Number of subjects: 304
Study: 9096189

Group type: EXPERIMENTAL
Intervention: Rifabutin in combination with a macrolide antibiotic (clarithromycin or azithromycin)
Number of subjects: 46
Study: 8329260

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1 mg/kg body weight
Number of subjects: 50

Group type: COMPARATOR
Intervention: Racemic ketamine 2 mg/kg body weight
Number of subjects: 50
Study: 3010782

Group type: EXPERIMENTAL
Intervention: Acyclovir therapy
Number of subjects: 107
Study: 30509638

Group type: EXPERIMENTAL
Intervention: Normal protein meal with phosphorus (500 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High protein meal with phosphorus (500 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal protein meal without phosphorus
Number of subjects: 12

Group type: COMPARATOR
Intervention: High protein meal without phosphorus
Number of subjects: 12
Study: 27973411

Group type: EXPERIMENTAL
Intervention: Low-GI SSB (isomaltulose)
Number of subjects: 13

Group type: COMPARATOR
Intervention: High-GI SSB (maltodextrin-sucrose)
Number of subjects: 13
Study: 24713309

Group type: EXPERIMENTAL
Intervention: Serial weekly transabdominal amnioinfusion (AI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Expectant management (Exp)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both AI and Exp
Number of subjects: 56
Study: 24066639

Group type: EXPERIMENTAL
Intervention: Counseling and relaxation practices (treated group)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Non-treated group (control)
Number of subjects: 110
Study: 21143403

Group type: EXPERIMENTAL
Intervention: Modified-release paracetamol (PEx) 80 mg/kg
Number of subjects: 9

Group type: COMPARATOR
Intervention: Immediate-release paracetamol (APAP-IR) 80 mg/kg
Number of subjects: 9
Study: 17664049

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 14

Group type: COMPARATOR
Intervention: No Dexamethasone
Number of subjects: 14
Study: 11872547

Group type: EXPERIMENTAL
Intervention: One stop clinic
Number of subjects: 670

Group type: COMPARATOR
Intervention: Dedicated breast clinic
Number of subjects: 670
Study: 9833950

Group type: EXPERIMENTAL
Intervention: Oral N-acetyl-L-cysteine (1,200 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 7867316

Group type: EXPERIMENTAL
Intervention: Schizophrenic patients
Number of subjects: 58

Group type: COMPARATOR
Intervention: Manic patients
Number of subjects: 58
Study: 2518872

Group type: EXPERIMENTAL
Intervention: Antacid (one tablet q.d.s. for 1.5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (one tablet q.d.s. for 1.5 days)
Number of subjects: 20
Study: 1053551

Group type: EXPERIMENTAL
Intervention: Sublingual isosorbide dinitrate (SISD)
Number of subjects: 20
Study: 31931647

Group type: EXPERIMENTAL
Intervention: methotrexate‐cytarabine‐thiotepa‐rituximab (MATRix)
Number of subjects: 0

Group type: COMPARATOR
Intervention: methotrexate‐cytarabine‐rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: methotrexate‐cytarabine
Number of subjects: 0
Study: 29960290

Group type: EXPERIMENTAL
Intervention: Reduqing granules
Number of subjects: 72

Group type: COMPARATOR
Intervention: Lianhuaqingwen capsules
Number of subjects: 72
Study: 25936840

Group type: EXPERIMENTAL
Intervention: LCPUFA-supplemented formula
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 69
Study: 23524197

Group type: EXPERIMENTAL
Intervention: Primes related to task difficulty (high difficulty words)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primes related to personal significance (people's first names)
Number of subjects: 0
Study: 21056640

Group type: EXPERIMENTAL
Intervention: Bergamot extract (BPF), given orally for 30 days
Number of subjects: 237
Study: 19054529

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study: 16894335

Group type: EXPERIMENTAL
Intervention: ERr 731 (one enteric-coated tablet daily for 12 weeks)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 15127021

Group type: EXPERIMENTAL
Intervention: Controlled slicing of the deciduous second molar between the ages of 8 and 9 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controlled slicing in 10‐ to 11‐year‐olds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extraction alone
Number of subjects: 0
Study: 11702035

Group type: EXPERIMENTAL
Intervention: PRECARD program (health educational computer program for coronary risk prediction and multifactorial prevention)
Number of subjects: 11765

Group type: EXPERIMENTAL
Intervention: Copenhagen Risk Score (new coronary risk score for myocardial infarction)
Number of subjects: 11765
Study: 9143783

Group type: EXPERIMENTAL
Intervention: Oral glibenclamide
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8190435

Group type: EXPERIMENTAL
Intervention: Oxytocin augmentation with intact chorioamnion
Number of subjects: 118

Group type: COMPARATOR
Intervention: Oxytocin augmentation with amniotomy and internal monitoring
Number of subjects: 118
Study: 3597738

Group type: EXPERIMENTAL
Intervention: Self-migration method in Earle's medium containing highly purified hyaluronic acid (Hya)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Traditional centrifugation method
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Self-migration method in medium containing Hya
Number of subjects: 211

Group type: COMPARATOR
Intervention: Media without Hya in self-migration method
Number of subjects: 211
Study: 31039778

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28094194

Group type: EXPERIMENTAL
Intervention: MABp1 (7.5 mg/kg every 2 weeks for 8 weeks)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: MABp1
Number of subjects: 333
Study: 26375841

Group type: EXPERIMENTAL
Intervention: MUFIPs (multifactorial intervention programs) including health education, weight-reduction/control program, quadriceps exercise training class, home-based exercise program, and home visit program
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no MUFIPs)
Number of subjects: 80
Study: 23150043

Group type: EXPERIMENTAL
Intervention: DRAMA‐RAMA
Number of subjects: 44

Group type: COMPARATOR
Intervention: Wii Dancing With the Stars
Number of subjects: 44
Study: 22145256

Group type: EXPERIMENTAL
Intervention: Desflurane coasting (in O2/air)
Number of subjects: 69
Study: 19853417

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Medication and Placebo
Number of subjects: 72
Study: 16903245

Group type: EXPERIMENTAL
Intervention: Laser CO2 surgery during pregnancy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Postpartum treatment (three months after delivery)
Number of subjects: 280
Study: 15039256

Group type: EXPERIMENTAL
Intervention: Technical training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Proprioceptive training
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Orthosis
Number of subjects: 52
Study: 11884000

Group type: EXPERIMENTAL
Intervention: Oral multivitamins from the first day of admission
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Nutritionally complete sipfeed from the second day in 'thin' patients
Number of subjects: 1561
Study: 9462474

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid tau concentrations
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Glial fibrillary acidic protein (GFAP) expression
Number of subjects: 43
Study: 7894959

Group type: EXPERIMENTAL
Intervention: Eccentric exercise repeated 48 hours after initial bout (Group 2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (Group 2)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (Group 1)
Number of subjects: 26
Study: 2955324

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Indomethacin 0.2 mg/kg
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Indomethacin (both dosages)
Number of subjects: 63
Study: 30081951

Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 137
Study: 26460504

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r) 800/100 mg once daily for 48 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r)
Number of subjects: 64

Group type: COMPARATOR
Intervention: TDF/FTC/EFV
Number of subjects: 64
Study: 24329424

Group type: EXPERIMENTAL
Intervention: CASA intervention (Collaborative Care to Alleviate Symptoms and Adjust to Illness)
Number of subjects: 17
Study: 22739371

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 15 μg/d (D3-15)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10 μg/d (D3-10)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 5 μg/d (D3-5)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Cholecalciferol 0 μg/d (P)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (any dose)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Fok I ff genotype
Number of subjects: 394
Study: 20842967

Group type: EXPERIMENTAL
Intervention: Consciously perceived prime
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unconsciously perceived prime
Number of subjects: 0
Study: 18479176

Group type: EXPERIMENTAL
Intervention: Lornoxicam quick-release tablet (QR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lornoxicam standard tablet (ST)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lornoxicam intramuscular injection (IM)
Number of subjects: 18
Study: 16140282

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean 11.30 mg/day)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Haloperidol (mean 4.87 mg/day)
Number of subjects: 263
Study: 14578242

Group type: EXPERIMENTAL
Intervention: Pramlintide at -15 min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pramlintide at 0 min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pramlintide at +15 min
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pramlintide at +30 min
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 11885177

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics
Number of subjects: 2973

Group type: COMPARATOR
Intervention: Postoperative antibiotics
Number of subjects: 2973
Study: 9151584

Group type: EXPERIMENTAL
Intervention: Standard machined titanium abutment (R(a) = 0.2 microns)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Highly polished ceramic abutment (R(a) = 0.06 microns)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both abutments
Number of subjects: 6
Study: 1422754

Group type: EXPERIMENTAL
Intervention: Lomoparan (750 anti-Xa units subcutaneously twice a day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Heparin-DHE 5000 (5000 units heparin and 0.5 mg dihydroergotamine subcutaneously twice a day)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Lomoparan
Number of subjects: 309

Group type: COMPARATOR
Intervention: Heparin-DHE 5000
Number of subjects: 309
Study: 6708033

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (5% dextrose in lactated Ringer's solution)
Number of subjects: 54
Study: 30753303

Group type: EXPERIMENTAL
Intervention: Outreach rehabilitation program (10 weeks, 30 sessions)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control (usual posthospital fracture care)
Number of subjects: 77
Study: 29975203

Group type: EXPERIMENTAL
Intervention: Preoperative fascia iliaca block with 40 ml ropivacaine 0.2%
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 80
Study: 27129477

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, couple‐ and parenting‐focused program designed to prevent stress‐spillover (n=70)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Information‐only control condition (n=69)
Number of subjects: 139
Study: 24670048

Group type: EXPERIMENTAL
Intervention: Vocal music (high and low intensity combined)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Instrumental music (high and low intensity combined)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no background music)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Vocal music
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Instrumental music
Number of subjects: 226
Study: 22226132

Group type: EXPERIMENTAL
Intervention: IV catheter without extension tubing (group 1)
Number of subjects: 121

Group type: COMPARATOR
Intervention: IV catheter with extension tubing (group 2)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Nurses' predictions of hemolysis
Number of subjects: 121
Study: 20337873

Group type: EXPERIMENTAL
Intervention: Overhead illumination (group 1)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Underneath illumination (group 2)
Number of subjects: 242
Study: 19087702

Group type: EXPERIMENTAL
Intervention: Gamma nail
Number of subjects: 1857

Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 1857
Study: 16123896

Group type: EXPERIMENTAL
Intervention: Hymecromone 800 mg p.o. with standardized meal (Biloptin, 40 gs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hymecromone i.v. with standardized meal (Biloptin, 40 gs)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo with standardized meal (Biloptin, 40 gs)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Hymecromone p.o. and i.v. with standardized meal (Biloptin, 40 gs)
Number of subjects: 20
Study: 12893113

Group type: EXPERIMENTAL
Intervention: Various antiepileptic drugs used to treat seizure disorder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical treatment of intractable epilepsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empirical and uncontrolled data
Number of subjects: 0
Study: 10393134

Group type: EXPERIMENTAL
Intervention: Bovine milk fat intake
Number of subjects: 123
Study: 8857217

Group type: EXPERIMENTAL
Intervention: Cycle ergometry test
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 2-mile run
Number of subjects: 100
Study: 1995721

Group type: EXPERIMENTAL
Intervention: Rhesus rotavirus vaccine (10^4 pfu)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: RIT 4237 vaccine (10^8 pfu)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study: 6089304

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily for 4 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 24
Study: 30846465

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28569647

Group type: EXPERIMENTAL
Intervention: Gain-framed depression help-seeking messages
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Loss-framed depression help-seeking messages
Number of subjects: 153
Study: 26786346

Group type: EXPERIMENTAL
Intervention: FORTA intervention (instruction on FORTA by a FORTA team)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Control group (no FORTA intervention)
Number of subjects: 409
Study: 24262102

Group type: EXPERIMENTAL
Intervention: MRI-ultrasound fusion biopsy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Visual targeting
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Targeted biopsy
Number of subjects: 125
Study: 22575075

Group type: EXPERIMENTAL
Intervention: 50 mg pregabalin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 200 mg pregabalin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 30 mg/kg pregabalin
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 100 mg/kg pregabalin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 38
Study: 20627696

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 154

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 154
Study: 17436845

Group type: EXPERIMENTAL
Intervention: Occupational therapy using a sensory integration approach (OT‐SI)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Activity Protocol
Number of subjects: 24

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 24
Study: 15821119

Group type: EXPERIMENTAL
Intervention: Analgesic Protocol (AP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician Discretion (PD)
Number of subjects: 0
Study: 11287373

Group type: EXPERIMENTAL
Intervention: Lines Cancellation (LC) task
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Multiple Features Targets Cancellation (MFTC) task
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Execution time for LC and MFTC tasks
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Mental Deterioration Battery (MDB)
Number of subjects: 148
Study: 9646878

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 125
Study: 7836622

Group type: EXPERIMENTAL
Intervention: Diet enriched with magnesium for 6 days
Number of subjects: 58

Group type: COMPARATOR
Intervention: Three different magnesium oxide preparations
Number of subjects: 58
Study: 2873966

Group type: EXPERIMENTAL
Intervention: Endralazine (10 mg to 30 mg per day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Hydralazine (75 mg to 200 mg per day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endralazine
Number of subjects: 30
Study: 29035134

Group type: EXPERIMENTAL
Intervention: HALNo
Number of subjects: 30

Group type: COMPARATOR
Intervention: LNo
Number of subjects: 30
Study: 27197920

Group type: EXPERIMENTAL
Intervention: Robotic radical cystectomy with intracorporeal diversion (iRARC)
Number of subjects: 82